CRCHUM
Montreal, Quebec, H2X 0A9, Canada
NCT Number: NCT05377190
Heart failure (HF) is one of the leading causes of hospitalization and death worldwide. Remote patient monitoring and digital therapeutics could help reduce the consumption of care for these patients (hospitalizations, emergency room visits) and optimize their management (education, medication optimization). This randomized study aims to evaluate the effects of the Continuum software solution in patients with heart failure, whether or not they are followed in specialized clinics. Heart failure is one of the main causes of hospitalization and death in the world. Evidence suggests that remote patient monitoring (RPM) and digital therapeutics (DTX solutions) can help improve care consumption (i.e. hospitalizations, emergency visits) and also support health care professionals to improve care (i.e. symptoms management, drug optimization). This randomised study aims to evaluate the effects of these two software solutions in the context of specialized HF clinics (HFC) and primary health care on health care consumption and clinical events.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Montreal, Quebec, H2X 0A9, Canada
According to Canadian recommendations, patients recently diagnosed with heart failure or with a recent hospitalization should have a medical follow-up every two to four weeks in order to optimize their treatment and quickly stabilize their condition. However, despite a network of specialized heart failure clinics in the province of Quebec, access to this service is still a challenge because of limited human resources and unequal geographic distribution. Only the most severely ill and unstable patients are followed in these clinics.
The Continuum project combines a remote patient monitoring solution with therapeutic interventions driven by a software to manage heart failure (also called digital therapeutics (DTx)). The patient can send her/his clinical data to the healthcare professional using a mobile application. Healthcare professionals receive not only these data in realtime with potential alerts but also a summarized report of these data and suggested therapeutic interventions.
Our hypotheses are that the Continuum solution, by combining RPM and DTx will 1) improve the workflow and the care trajectory of patients in heart failure clinics resulting in a reduction of cost per patient followed and 2) accelerate drug optimization so they can fully benefit from the recommended therapies for their specific condition.
The general objective of this project is to assess in outpatients the effectiveness of the Continuum solution to reduce healthcare costs and to support medication optimization over a period of 12 weeks.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
HFC-IN
Inclusion criteria
HFC-OUT
Inclusion criteria
Exclusion criteria
for HFC-IN and HFC-OUT:
Combination of a mobile application (with remote monitoring) and digital therapeutics
No mobile application or digital therapeutics are used
Combination of a mobile application (without remote monitoring) and digital therapeutics
Time frame: 12 weeks
Cost analysis on number of hospital (planned or unplanned) ambulatory visits, emergency visits, consultations and hospitalizations
Time frame: 12 weeks
Change in guideline-directed medical Therapy optimization between groups before and after intervention by medication classes.
Time frame: 12 weeks
Change in guideline-Directed Medical Therapy optimization between groups before and after intervention by medication doses.
Time frame: 12 weeks
Cost analysis on number of hospital (planned or unplanned) ambulatory visits, emergency visits, consultations and hospitalizations during intervention
Time frame: 12 weeks
Compare guideline-Directed Medical Therapy optimization between groups before and after intervention by medication classes
Time frame: 12 weeks
Compare guideline-Directed Medical Therapy optimization between groups before and after intervention by medication doses
Time frame: 12 weeks
Differences before-after between groups in number of main clinical events including unplanned appointments, emergency consults, all-cause or heart-failure hospitalizations, deaths
Time frame: 12 weeks
Differences in score before and after
Time frame: 12 weeks
Differences in score before and after
Time frame: 12 weeks
A reduction of at least one class in New York Heart Association (NYHA) scale
Time frame: 12 weeks
Reduction in NTproBNP greater than 30%
Time frame: 12 weeks
Percentage of recommended heart failure drugs prescribed
Centre hospitalier de l'Université de Montréal (CHUM)
Other
Continuum: Digital Health as Part of the Care Trajectory of Heart Failure Outpatients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03892148
Acute Heart Failure, Cardiovascular Diseases
Annecy, France
View Trial DetailsNCT05295641
Acute Heart Failure (AHF), Cardiovascular Diseases
Manhasset, New York, United States
View Trial DetailsNCT04829591
Acute Heart Failure, Cardiovascular Diseases
Amman, Jordan
View Trial DetailsNCT05480345
Cardiovascular Diseases, Chronic Heart Failure
Kaunas, Lithuania
View Trial Details